Compare SSII & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSII | SGP |
|---|---|---|
| Founded | N/A | 2019 |
| Country | India | United States |
| Employees | 483 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 774.5M | 932.9M |
| IPO Year | N/A | N/A |
| Metric | SSII | SGP |
|---|---|---|
| Price | $3.85 | $24.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 37.3K | ★ 59.1K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.02 | $20.15 |
| 52 Week High | $11.87 | $30.56 |
| Indicator | SSII | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 34.79 | 47.66 |
| Support Level | $3.70 | $20.95 |
| Resistance Level | $5.14 | $26.55 |
| Average True Range (ATR) | 0.28 | 1.42 |
| MACD | -0.05 | 0.19 |
| Stochastic Oscillator | 15.00 | 52.86 |
SS Innovations International Inc is a commercial-stage surgical robotics company. It designs, manufactures, and markets a surgical robotic system called the SSi Mantra Surgical Robotic System (the SSi Mantra) intended for use in urology, general, gynecology, colorectal, gastroenterology, head and neck, thoracic, and cardiac surgeries. Additionally, the company offers a suite of stapling, energy, and core instrumentation for its surgical systems, under the brand name of SSi Mudra.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.